Eyenovia, Inc. reported its financial results for the third quarter ended September 30, 2024, on November 12, 2024. The company announced a net loss of $7.89 million, which represents a 7.5% widening compared to the third quarter of 2023.
The company also provided a corporate update, noting the advancement of its Phase 3 CHAPERONE study for MicroPine and the commencement of manufacturing for Mydcombi in its second-generation Optejet device. Additionally, Eyenovia announced the U.S. launch and commercial availability of clobetasol propionate ophthalmic suspension 0.05%.
Andrew Jones was appointed as Chief Financial Officer during the quarter. Despite these operational updates, the increased net loss indicates ongoing financial challenges for the company.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.